This technology introduces novel compositions and methods using mutated forms of TIMP-2 to precisely regulate extracellular MMP-2 activity, offering targeted control over tissue remodeling processes.
Background: Matrix metalloproteinase-2 (MMP-2) plays a vital role in remodeling the extracellular matrix, which is essential for normal physiological functions such as tissue repair. However, its dysregulation is strongly linked to pathological conditions, including cancer metastasis and other diseases characterized by abnormal tissue degradation. Conventional methods for controlling MMP-2 activity have lacked specificity and efficacy, creating a need for innovative strategies that modulate this enzyme in a targeted manner. This need inspired research into the regulation of MMP-2 by tissue inhibitors of metalloproteinases, particularly focusing on modifications through phosphorylation to achieve better control.
Technology Overview: This invention centers on the use of engineered TIMP-2 mutants that selectively alter the activity of extracellular MMP-2 by modifying phosphorylation sites on TIMP-2. These mutants are designed either to enhance or inhibit MMP-2 activity, depending on therapeutic requirements. By targeting the phosphorylation events that regulate TIMP-2’s interaction with MMP-2, the technology enables fine-tuning of enzyme activity rather than complete inhibition, which is a novel approach compared to existing broad-spectrum inhibitors. The technology is supported by detailed biochemical studies demonstrating how specific amino acid changes in TIMP-2 influence MMP-2 function. Experimental data validate that these mutants can effectively regulate the enzymatic activity in vitro, providing a controlled mechanism to adjust extracellular matrix remodeling processes. This targeted modulation holds the promise of addressing diseases where excessive or insufficient MMP-2 activity contributes to disease progression, such as cancer and fibrotic disorders. The ability to selectively enhance or inhibit MMP-2 expands therapeutic options, potentially reducing side effects associated with non-specific metalloproteinase inhibition.
https://suny.technologypublisher.com/files/sites/adobestock_1828918781.jpeg Photo for reference only, not a depiction of the invention.
Advantages: • Precise modulation of MMP-2 activity through targeted phosphorylation site mutations on TIMP-2. • Potential to both enhance and inhibit MMP-2, providing flexible therapeutic strategies. • Reduced likelihood of off-target effects compared to non-specific metalloproteinase inhibitors. • Novel biochemical approach enabling regulation rather than complete suppression of enzyme activity. • Supported by experimental evidence validating efficacy and mechanism of action.
Applications: • Treatment of cancers where MMP-2 contributes to tumor invasion and metastasis through extracellular matrix degradation. • Therapies for fibrotic diseases involving abnormal tissue remodeling and matrix deposition. • Potential use in controlled wound healing processes by regulating tissue repair through MMP-2 activity. • Research tools for studying extracellular matrix dynamics and metalloproteinase regulation in various pathological contexts.
Intellectual Property Summary: Patented: 12,006,351 https://patents.google.com/patent/US12006351B2/en
Stage of Development: TRL 3 – Experimental Proof of Concept
Licensing Status: This technology is available for licensing.